You are viewing the site in preview mode

Skip to main content

Table 2 Univariate and multivariate analyses of progression-free survival and overall survival

From: Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data

  OS PFS
Univariate Multivariate Univariate Multivariate
Characteristics Median p-value HR 95% CI p-value Median p-value HR 95% CI p-value
Age, years
  < 70 15.2 0.645     7.4 0.236    
  ≥ 70 10.3      6.4     
Sex
 Male 12.6 0.223     7.7 0.171    
 Female 14.9      3.9     
ECOG PS
 0 or 1 16.5 < 0.0001    0.001 7.7 0.007    0.028
 2 4.1   5.28 2.06–13.54   2.7   2.67 1.11–6.41  
Disease status
 Primary metastatic 14.9 0.762     7.4 0.825    
 Recurrent 9.9      6.4     
Histology
 Well or moderate 12.6      7.8     
 Poor 12.8 0.733     5.9 0.815    
 Signet ring cell 5.9      3.9     
 Combined, others 4.5      3.4     
HER2 status
 IHC 3+ 12.6 0.658     6.9 0.938    
 IHC 2+ with SISH + 17.0      6.8     
Liver metastasis
 No 15.2 0.312     8.3 0.066    0.137
 Yes 10.0      6.4   1.66 0.85–3.23  
Peritoneal metastasis
 No 14.9 0.413     6.9 0.621    
 Yes 10.0      5.0     
Amount of ascites
 No/small/moderate 15.2 0.001    0.005 7.4 0.016    0.073
 Massive 5.9   4.54 1.57–13.09   3.9   2.47 0.92–6.65  
Surgical resection
 No 9.9 0.004    0.025 5.9 0.002    0.022
 Surgery 30.8   0.25 0.08–0.84   20.3   0.29 0.10–0.84  
Chemotherapy
 Capecitabine/Cisplatin 12.6 0.649     6.5 0.795    
 5-FU/Cisplatin 12.8      8.3     
  1. OS overall survival, PFS progression-free survival, HR hazard ratio, 95% CI 95% confidence interval, ECOG Eastern Cooperative Oncology Group, PS performance status, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, SISH silver-enhanced in situ hybridization, FU fluorouracil
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us